There is no good evidence about the effectiveness of Tamiflu (oseltamivir) and Relenza (zanamivir) for influenza prevention and treatment. This is the tough claim made by Cochrane Collaboration and the British Medical Journal (BMJ), based on the extended systematic review they just published about the use of neuraminidase inhibitors against influenza.
Their study is entirely based on complete clinical study reports, trial registries, electronic databases, regulatory archives and correspondence with manufacturers, which correspond to more than 150,000 pages of documents; more specifically, the